Insulet Corporation Market Cap ($10.37 Billion)
Market Cap & Net Worth: Insulet Corporation (PODD)
Insulet Corporation market cap. Insulet Corporation (NASDAQ:PODD) has a market capitalization of $10.37 Billion ($10.37 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2109 globally and #800 in its home market, demonstrating a 1.05% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Insulet Corporation's stock price $149.68 by its total outstanding shares 69264674 (69.26 Million). Also see PODD cash flow conversion for how efficiently the company converts equity into cash flow.
Insulet Corporation Market Cap History (2015–2026)
Insulet Corporation market cap history from 2015 to 2026. Data shows growth from $2.62 Billion to $10.37 Billion (15.41% CAGR). Check Insulet Corporation stock quote for real-time trading data and today's change.
Index Memberships
Insulet Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$61.47 Trillion | 0.04% | #459 of 503 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.40% | #44 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.03% | #243 of 3165 |
Weight: Insulet Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Insulet Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Insulet Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PODD year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.27x
Insulet Corporation's market cap is 7.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
79.68x
Insulet Corporation's market cap is 79.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.61 Billion | $366.99 Million | -$28.88 Million | 7.11x | N/A |
| 2017 | $4.78 Billion | $463.77 Million | -$26.83 Million | 10.31x | N/A |
| 2018 | $5.49 Billion | $563.82 Million | $3.29 Million | 9.74x | 1668.92x |
| 2019 | $11.86 Billion | $738.20 Million | $11.60 Million | 16.06x | 1022.25x |
| 2020 | $17.71 Billion | $904.40 Million | $6.80 Million | 19.58x | 2603.84x |
| 2021 | $18.43 Billion | $1.10 Billion | $16.80 Million | 16.77x | 1096.98x |
| 2022 | $20.39 Billion | $1.31 Billion | $4.60 Million | 15.62x | 4432.79x |
| 2023 | $15.03 Billion | $1.70 Billion | $206.30 Million | 8.86x | 72.85x |
| 2024 | $18.08 Billion | $2.07 Billion | $418.30 Million | 8.73x | 43.23x |
| 2025 | $19.69 Billion | $2.71 Billion | $247.10 Million | 7.27x | 79.68x |
Competitor Companies of PODD by Market Capitalization
Companies near Insulet Corporation in the global market cap rankings as of November 1, 2026. Also see total assets of Insulet Corporation for a full breakdown of the balance sheet.
Key companies related to Insulet Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $184.67 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #215 globally with a market cap of $111.95 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #241 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $184.67 Billion | $106.20 |
| #215 | Stryker Corporation | NYSE:SYK | $111.95 Billion | $291.86 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $96.54 |
| #241 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Insulet Corporation (2015–2026)
Market capitalization of Insulet Corporation from 2015 to today. Between 2015 and today, Insulet Corporation's market cap moved from $2.62 Billion to $ 10.37 Billion, with a yearly change of 15.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.37 Billion | -47.34% |
| 2025 | $19.69 Billion | +8.88% |
| 2024 | $18.08 Billion | +20.32% |
| 2023 | $15.03 Billion | -26.30% |
| 2022 | $20.39 Billion | +10.64% |
| 2021 | $18.43 Billion | +4.08% |
| 2020 | $17.71 Billion | +49.32% |
| 2019 | $11.86 Billion | +115.83% |
| 2018 | $5.49 Billion | +14.96% |
| 2017 | $4.78 Billion | +83.12% |
| 2016 | $2.61 Billion | -0.34% |
| 2015 | $2.62 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Insulet Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.37 Billion USD |
| MoneyControl | $10.37 Billion USD |
| MarketWatch | $10.37 Billion USD |
| marketcap.company | $10.37 Billion USD |
| Reuters | $10.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more